Schizophrenia – Japan Drug Forecast and Market Analysis to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions). A multitude of antipsychotic products are currently available for the pharmacological management of schizophrenia, many of which are already available as inexpensive generics. Further patent and exclusivity losses in key franchises throughout the forecast period will act as a barrier to growth in the 7MM, making the schizophrenia market more competitive and crowded. Growth in the schizophrenia market is expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards significant unmet needs. GlobalData estimates that drug sales for schizophrenia in Japan reached approximately $659.3m during 2015, making it the second largest market within the 7MM. Similar to the US and 5EU markets, the increase in Japan’s market value will mainly be a result of emerging pipeline assets that are expected to launch from early to midway through the forecast period, which will likely have a high ACOT compared to the widely available generic drugs. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Schizophrenia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in the Japan from 2015-2025.

Analysis of the impact of key events as well the drivers and restraints affecting the Japan Schizophrenia market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2015-2025 in the Japan.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Classification

3.3Symptoms

3.4Course

3.5Prognosis

4Disease Management

4.1Diagnosis Overview

4.1.1Clinical Evaluation

4.2Treatment Overview

4.2.1Treatment Initiation

4.2.2Maintenance Treatment

4.2.3Treatment of Breakthrough Episodes

4.2.4Long-Acting Injectables

4.2.5Treatment-Resistance

4.2.6Acute Agitation

4.2.7Adjunctive Psychotherapy

4.3Treatment Guidelines and Leading Prescribed Drugs

4.4Japan

5Competitive Assessment

5.1Overview

5.2Product Profiles – Atypical Antipsychotics

5.2.1Abilify (aripiprazole)

5.2.2Aristada (aripiprazole lauroxil)

5.2.3Clozapine (widely genericized)

5.2.4Fanapt (iloperidone)

5.2.5Geodon (ziprasidone)

5.2.6Invega (paliperidone)

5.2.7Latuda (lurasidone)

5.2.8Lonasen (blonanserin)

5.2.9Rexulti (brexpiprazole)

5.2.10Risperdal (risperidone)

5.2.11Saphris (asenapine)

5.2.12Seroquel (quetiapine)

5.2.13Vraylar (cariprazine)

5.2.14Zyprexa (olanzapine)

5.3Product Profiles – Typical Antipsychotics

5.3.1Typical Antipsychotics

5.3.2Adasuve (Staccato loxapine)

5.4Other Therapeutic Classes

6Unmet Needs and Opportunities

6.1Overview

6.2Development of Cognitive-Enhancing Drugs

6.2.1Unmet Need

6.2.2Gap Analysis

6.2.3Opportunity

6.3Development of Drugs to Treat Negative Symptoms

6.3.1Unmet Need

6.3.2Gap Analysis

6.3.3Opportunity

6.4Improved Treatment Options for Treatment-Resistant Patients

6.4.1Unmet Need

6.4.2Gap Analysis

6.4.3Opportunity

6.5Development of Drugs with Enhanced Safety Profiles

6.5.1Unmet Need

6.5.2Gap Analysis

6.5.3Opportunity

6.6Development of Drugs to Increase Compliance

6.6.1Unmet Need

6.6.2Gap Analysis

6.6.3Opportunity

7Pipeline Assessment

7.1Overview

7.1.1Clinical Trials by Class of Therapy

7.2Promising Drugs in Clinical Development

7.2.1ALKS-3831

7.2.2ITI-007

7.2.3Lu AF35700

7.2.4MIN-101

7.2.5Risperidone implant

7.2.6Risperidone ISM

7.2.7RBP-7000

7.2.8AVN-211

7.2.9NaBen

7.3Other Drugs in Development

8Market Outlook

8.1Japan

8.1.1Forecast

8.1.2Key Events

8.1.3Drivers and Barriers

9Appendix

9.1Bibliography

9.2Abbreviations

9.3Methodology

9.4Forecasting Methodology

9.4.1Diagnosed Schizophrenia Patients

9.4.2Percent Drug-Treated Patients

9.4.3Launch and Patent Expiry Dates

9.4.4General Pricing Assumptions

9.4.5Individual Drug Assumptions

9.4.6Generic Erosion

9.4.7Pricing of Pipeline Agents

9.5Primary Research – KOLs Interviewed for this Report

9.6Primary Research – Prescriber Survey

9.7About the Authors

9.7.1Analyst

9.7.2Therapy Area Director

9.7.3Epidemiologist

9.7.4Managing Epidemiologist

9.7.5Global Director of Therapy Analysis and Epidemiology

9.8About GlobalData

9.9Disclaimer

Table

Table 1: DSM-V Schizophrenia Specifiers

Table 2: Classification of Schizophrenia According to DSM-IV and ICD-10

Table 3: Other Schizophrenia Spectrum Disorders, 2015

Table 4: Symptoms of Schizophrenia

Table 5: Treatment Guidelines for Schizophrenia

Table 6: Most Prescribed Drugs for Schizophrenia in the 7MM, 2015

Table 7: Country Profile – Japan

Table 8: Leading Treatments for Schizophrenia, 2015

Table 9: Product Profile – Abilify

Table 10: Efficacy Results for Abilify in Schizophrenia Trials

Table 11: Efficacy Results for Abilify in Schizophrenia Trials

Table 12: AEs at =2% Incidence in Schizophrenia and Bipolar I Disorder Trials of Abilify

Table 13: AEs at =2% Incidence in a Schizophrenia Trial of Abilify Maintena

Table 14: Abilify SWOT Analysis, 2016

Table 15: Product Profile – Aristada

Table 16: Efficacy Results for Aristada in Schizophrenia Trial

Table 17: AEs at =2% Incidence in a Schizophrenia Trial of Aristada

Table 18: Aristada SWOT Analysis, 2016

Table 19: Product Profile – Clozapine

Table 20: Efficacy Results for Clozapine in Treatment-Resistant Schizophrenia Patients

Table 21: AEs at =5% Incidence in a Short-Term Trial of Clozapine

Table 22: AEs at =2% Incidence in All Clinical Trials of Clozapine (Excluding InterSePT)

Table 23: AEs at =10% Incidence During the InterSePT Trial of Clozapine

Table 24: Clozapine SWOT Analysis, 2016

Table 25: Product Profile – Fanapt

Table 26: AEs at =2% Incidence in Short-Term Trials of Fanapt

Table 27: Fanapt SWOT Analysis, 2016

Table 28: Product Profile – Geodon

Table 29: AEs at =2% Incidence in Schizophrenia Trials of Geodon

Table 30: Geodon SWOT Analysis, 2016

Table 31: Product Profile – Invega

Table 32: Efficacy of Invega Sustenna in Adult Schizophrenia Short-Term Trials

Table 33: AEs at =2% Incidence in Adult Schizophrenia Trials of Invega

Table 34: AEs at =2% Incidence in an Adolescent Schizophrenia Trial of Invega

Table 35: AEs at =2% Incidence in Schizophrenia Trials of Invega Sustenna

Table 36: AEs at =2% Incidence in a Long-Term Maintenance Trial of Invega Trinza in Schizophrenic Patients

Table 37: Invega SWOT Analysis, 2016

Table 38: Product Profile – Latuda

Table 39: Efficacy Results for Latuda in Schizophrenia Trials

Table 40: AEs at =2% Incidence in Schizophrenia Trials of Latuda

Table 41: Latuda SWOT Analysis, 2016

Table 42: Product Profile – Lonasen

Table 43: Efficacy Results for Lonasen in Haloperidol-Controlled Clinical Trial

Table 44: Efficacy Results for Lonasen in Risperidone-Controlled Clinical Trial

Table 45: AEs at =5% Incidence in a Short-Term Trial of Lonasen

Table 46: Lonasen SWOT Analysis, 2016

Table 47: Product Profile – Rexulti

Table 48: Efficacy Results for Rexulti in Short-Term Schizophrenia Trials

Table 49: AEs at =2% Incidence in Schizophrenia Trials of Rexulti

Table 50: Rexulti SWOT Analysis, 2016

Table 51: Product Profile – Risperdal

Table 52: Efficacy Results for Risperdal Consta in a 12-Week Schizophrenia Study

Table 53: AEs at =2% Incidence in Adult Schizophrenia Trials of Risperdal

Table 54: AEs at =5% Incidence in a Pediatric Schizophrenia Trial of Risperdal

Table 55: AEs at =5% Incidence in an Adult Schizophrenia Trial of Risperdal Consta

Table 56: Risperdal SWOT Analysis, 2016

Table 57: Product Profile – Saphris

Table 58: Efficacy Results for Saphris in Short-Term Schizophrenia Trials

Table 59: AEs at =2% Incidence in Schizophrenia Trials of Saphris

Table 60: Saphris SWOT Analysis, 2016

Table 61: Product Profile – Seroquel

Table 62: Efficacy Results for Seroquel in a Six-Week Schizophrenia Study

Table 63: Efficacy Results for Seroquel in Short-Term Schizophrenia Studies

Table 64: Efficacy Results for Seroquel XR in Schizophrenia Trials

Table 65: AEs at =2% Incidence in Adult Schizophrenia and Bipolar Mania Trials of Seroquel

Table 66: AEs at =2% Incidence in a Short-Term Trial of Seroquel in Schizophrenic Adolescents

Table 67: AEs at =2% Incidence in Six-Week Trials of Seroquel XR in Schizophrenic Adults

Table 68: Seroquel SWOT Analysis, 2016

Table 69: Product Profile – Vraylar

Table 70: Efficacy Results for Vraylar in a Six-Week Schizophrenia Study

Table 71: Efficacy Results for Vraylar in Short-Term Schizophrenia Studies

Table 72: AEs at =2% Incidence in Short-Term Schizophrenia Trials of Vraylar

Table 73: Vraylar SWOT Analysis, 2016

Table 74: Product Profile – Zyprexa

Table 75: AEs at =5% Incidence in Adult Schizophrenia Trials of Zyprexa

Table 76: AEs at =2% Incidence in Short-Term Trials of Zyprexa

Table 77: AEs at =1% Incidence in Adult Schizophrenia Trials of Zyprexa IntraMusular

Table 78: AEs at =5% Incidence in Adolescent Schizophrenia Trials of Zyprexa

Table 79: AEs Reported at =2% Incidence in a Schizophrenia Trial of Zyprexa Relprevv

Table 80: Zyprexa SWOT Analysis, 2016

Table 81: Typical antipsychotics SWOT Analysis, 2016

Table 82: Product Profile – Adasuve

Table 83: Efficacy Results for Adasuve in Agitation Trial of Schizophrenia Patients

Table 84: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve

Table 85: Adasuve SWOT Analysis, 2016

Table 86: Summary of Minor Therapeutic Classes, 2015

Table 87: Unmet Need and Opportunity in Schizophrenia

Table 88: Product Profile – ALKS-3831

Table 89: ALKS-3831 SWOT Analysis, 2016

Table 90: Product Profile – ITI-007

Table 91: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial

Table 92: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007

Table 93: ITI-007 SWOT Analysis, 2016

Table 94: Product Profile – Lu AF35700

Table 95: Lu AF35700 SWOT Analysis, 2016

Table 96: Product Profile – MIN-101

Table 97: Efficacy Results for MIN-101 in a 12-Week Phase IIb Schizophrenia Study

Table 98: Safety Evaluation of MIN-101 Phase IIa Clinical Trial in Schizophrenia

Table 99: AEs at =5% Incidence in a Phase IIb Schizophrenia Trial of MIN-101

Table 100: Safety Evaluation of MIN-101 Phase IIb Clinical Trial in Schizophrenia

Table 101: MIN-101 SWOT Analysis, 2016

Table 102: Product Profile – Risperidone Implant

Table 103: Risperidone Implant SWOT Analysis, 2016

Table 104: Product Profile – Risperidone ISM

Table 105: Risperidone ISM SWOT Analysis, 2016

Table 106: Product Profile – RBP-7000

Table 107: Efficacy Results for RBP-7000 in a Phase III Schizophrenia Trial

Table 108: AEs reported in a Phase III Schizophrenia Trial of RBP-7000A

Table 109: RBP-7000 SWOT Analysis, 2016

Table 110: Product Profile – AVN-211

Table 111: Attention tests and measures evaluated in a Phase IIa Schizophrenia Trial of AVN-211

Table 112: Psychometric Results in a Phase IIa Schizophrenia Trial of AVN-211

Table 113: Results of the Attention Measures that Showed Significant Changes in a Phase IIa Schizophrenia Trial of AVN-211

Table 114: AVN-211 SWOT Analysis, 2016

Table 115: Product Profile – NaBen

Table 116: PANSS Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia

Table 117: Other Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia

Table 118: Cognitive Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia

Table 119: NaBen SWOT Analysis, 2016

Table 120: Drugs in Development for Schizophrenia, 2015

Table 121: Key Events Impacting Sales for Schizophrenia in Japan, 2015–2025

Table 122: Schizophrenia Market in Japan – Drivers and Barriers, 2015–2025

Table 123: Key Launch Dates

Table 124: Key Patent/Exclusivity Expiries

Table 125: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country

Figures

Figure 1: Longitudinal Course of Schizophrenia

Figure 2: Schizophrenia Therapeutics – Class of Therapy, 2016

Figure 3: Schizophrenia – Promising Late-Stage Phase IIb–III Pipeline Drugs, 2016

Figure 4: Competitive Assessment of Promising Late-Stage Pipeline Agents in Schizophrenia, 2015–2025

Figure 5: Clinical and Commercial Positioning of ALKS-3831

Figure 6: Clinical and Commercial Positioning of ITI-007

Figure 7: Clinical and Commercial Positioning of Lu AF35700

Figure 8: Clinical and Commercial Positioning of MIN-101

Figure 9: Clinical and Commercial Positioning of the Risperidone Implant

Figure 10: Clinical and Commercial Positioning of Risperidone ISM

Figure 11: Clinical and Commercial Positioning of RBP-7000

Figure 12: Clinical and Commercial Positioning of AVN-211

Figure 13: Clinical and Commercial Positioning of NaBen

Figure 14: Sales for Schizophrenia in Japan by Drug Class, 2015–2025

Frequently asked questions

Schizophrenia – Japan Drug Forecast and Market Analysis to 2025 thematic reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Schizophrenia – Japan Drug Forecast and Market Analysis to 2025 in real time.

  • Access a live Schizophrenia – Japan Drug Forecast and Market Analysis to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.